Best Practices for Fundraising and M&A Due Diligence Chinese 并购交易中的意外事件可能会导致交易延迟,甚至完全破坏交易。但如果您知道如何预防这些意外事件,它们是可以避免的。 Due Diligence Fundraising Mergers & Acquisitions Whitepapers
Best Practices for Fundraising and M&A Due Diligence Korean 인수 합병 거래 중 예상하지 못한 일이 벌어진다면 거래의 지연을 야기할 수 있으며 심지어 거래를 완전히 무마시킬 수도 있습니다. 그러나 그러한 상황을 대비하여 불미스러운 일을 피할 수 있습니다. Due Diligence Fundraising Whitepapers
Seven Habits of Highly Effective Data Rooms Chinese 您的尽职调查过程的速度和有效性都会直接影响最终的交易价值。在潜在交易之前做好尽职调查的准备可以让您采取行动并创造机会。 Virtual Data Room Whitepapers
Seven Habits of Highly Effective Data Rooms Korean 실사 프로세스의 속도와 효율성은 모두 최종 거래 가치에 직접적인 영향을 미칩니다. 잠재적인 거래에 앞서 미리 실사에 대비하면 조치를 취하여 기회를 창출할 수 있습니다. Virtual Data Room Whitepapers
Capital Raising the Investor Landscape Start writing here...... Capital to raise Investment Whitepapers
Valuation of Your Early Drug Candidate In this whitepaper, author Linda Pullan reviews the different techniques, key variables, and characteristics of what makes a drug candidate more valuable to a partner. Life Sciences Series Valuation Whitepapers
Best Practices for Fundraising and M&A Due Diligence This whitepaper explores the importance of establishing early goals and objectives for the process, how to get the right people to ask the right questions in advance of the process, how to build credibility by defining goals and demonstrating they can be achieved, and much more. Due Diligence Finance Fundraising Mergers & Acquisitions Whitepapers
Getting Ready for a Biopharma Partnering Deal This whitepaper provides actionable advice for Biotech business development leaders on how to get ready for a partnering deal. Best Practices & Trends BioPharma Licensing & Partnering Life Sciences Series Whitepapers
The Nuts & Bolts of Due Diligence in Biopharma Partnering This whitepaper focuses on best practices in due diligence with the goal of forming productive biopharma partnerships. Best Practices & Trends BioPharma Due Diligence Licensing & Partnering Life Sciences Series Whitepapers
What's Hot and What's Not in Oncology Licensing in 2020? In this whitepaper, Linda Pullan, PhD of Pullan Consulting and our panel of experts provided insights in oncology and immuno-oncology in 2020. Best Practices & Trends BioPharma Life Sciences Other Topics Series Whitepapers
How to Win at the Partnering Game In this white paper, Linda Pullan provides a review of the rules of the partnering game – whether it’s partnering from preclinical to late clinical development – to provide an understanding of what to expect in moving from introductions to negotiations of a license or acquisition and how to win with a clear strategy. Best Practices & Trends BioPharma Licensing & Partnering Life Sciences Series Whitepapers
Non-Immuno-Oncology and Immuno-Oncology Partnering and Development: What’s the Role of Non-IO in an IO World? This whitepaper discusses the role of non-immuno-oncology therapies for cancer in a world where immuno-oncology is playing a greater role. Best Practices & Trends BioPharma Life Sciences Other Topics Series Whitepapers